Acumen Pharmaceuticals(US:ABOS)2025-11-11 12:00Financial Performance Highlights - The company achieved a gross margin expansion of 14 percentage points from 132% in 3Q24 to 146% in 2Q25 and 147% in 3Q25[24] - Adjusted EBITDA margin increased by 09 percentage points from 52% in 3Q24 to 61% in 3Q25[24] - Cash generation reached R$ 1669 million in 3Q25[26] - Net debt to adjusted pro forma EBITDA improved sequentially by 016x, reaching 417x[27] Revenue Analysis - Hospitals and Clinics revenue increased by 170% from R$286 million in 3Q24 to R$335 million in 3Q25, but decreased by 86% from R$6352 million in 9M24 to R$5969 million in 9M25[39] - Laboratories and Vaccines revenue increased by 225% from R$2189 million in 3Q24 to R$2001 million in 3Q25[39] - Retail channel revenue grew by 46% from R$710 million in 9M24 to R$742 million in 9M25[44] - Services channel revenue increased by 62% from R$221 million in 3Q24 to R$231 million in 3Q25[44] Expense Management - Total operating expenses decreased by 759% from R$570759 million in 3Q24 to R$137740 million in 3Q25[48] - Selling expenses (excluding D&A) decreased by 86% from R$99888 million in 3Q24 to R$91299 million in 3Q25[48] - Losses on impairment of assets decreased significantly by 937% from R$111728 million in 3Q24 to R$7093 million in 3Q25[48] DIFAL Impact - A positive impact of R$3146 million in 3Q25 due to the reversal of the full provision for DIFAL 2022 and gain of shares of DIFAL 2021, net of legal fees[33] - Remaining balance of R$950 million in provisions related to 2021 DIFAL as of the end of September 2025[34] Working Capital and Cash Flow - Cash cycle improved to 55 days in 3Q25, which is 2 days shorter than in 2Q25[26] - Free cash flow was R$166922 million in 3Q25, compared to R$504645 million in 3Q24[64]